CUVCPES and CUTEC warmly invite you to join an inspiring, insightful and honest discussion about forging a career in bio-innovation. We are excited to host an accomplished panel of bio-innovators with vast expertise across biotech and life science consulting, entrepreneurship and investing. The speakers will discuss their professional journeys and share key learnings for success. This event is open to everyone but will be particularly relevant to aspiring individuals within the Cambridge ecosystem who are in the early stages of launching their own transformative careers in bio-innovation. The panel discussion will include a live Q/A session, followed by a networking session.
Dr Michael Anstey is a Partner specialising in life science investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan. Michael was also co-founder of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked at Oxford Capital Partners, where he focused on investing in early stage life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford. Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.
Miranda Weston-Smith helps early stage biomedical businesses attract investment and develop their business strategy. She founded and runs BioBeat connecting entrepreneurs with the leaders in biotech. She has worked with many entrepreneurs on fundraising, business planning and technology transfer. She brings experience from Cambridge Enterprise and the seed capital firm, Cambridge Research and Innovation. She co-founded Cambridge Network with Hermann Hauser. Miranda studied Natural Sciences at the University of Cambridge and has a Diploma from the Chartered Institute of Management Accountants. She is a Fellow of the Linnean Society and has edited eight science books.
Susan Hill is Chief Executive Officer of Mestag Therapeutics and Venture Partner at SV Health Investors. Susan has 20 years’ experience in biotech, operating in UK, Europe and US based companies. Susan joined Mestag from clinical complement company Gyroscope Therapeutics, where she served as Chief Business Officer and helped to drive the company’s $62m Series B. Prior, she was founding Chief Executive Officer of Orbit Biomedical ($12m Series A) and Chief Business Officer of Freeline Therapeutics. Previously, Susan served in the Business & Corporate Development team at Alexion (ALXN), and during an 8-year tenure at Merck Serono (MRK) in a series of Corporate & Business Development and Portfolio Management roles. Susan began her career in strategy consulting/M&A, followed by a 3-year tenure leading biotech seed investments. She has an MA and PhD from the University of Cambridge and is a previous Fellow of the Securities Institute.